General
Preferred name
VARDENAFIL
Synonyms
VARDENAFIL HYDROCHLORIDE ()
Vivanza ()
Levitra ()
Vardenafil HCl Trihydrate ()
BAY38-9456 ()
VARDENAFIL DIHYDROCHLORIDE ()
Vardenafil (hydrochloride trihydrate) ()
Vardenafil (hydrochloride) ()
BAY38-9456, Levitra, Staxyn ()
Vardenafil hydrochloride trihydrate ()
Vardenafil (hydrochloride hydrate) ()
Vardenafil-d5 ()
Vardenafil hydrochloride anhydrous ()
Vardenafil monohydrochloride ()
BAY 38-9456 ()
Staxyn ()
Vardenafil hydrochloride hydrate ()
Vardenafil hcl ()
BAY-38-9456 ()
Nuviva ()
BAY-389456 ()
NSC-759103 ()
Vardenafil trihydrate ()
Vardenafil (CRM) ()
P&D ID
PD009681
CAS
224785-90-4
1193386-64-9
224785-91-5
224789-15-5
330808-88-3
1189685-70-8
Tags
available
drug
drug candidate
Approved by
FDA
First approval
2003
Drug indication
Erectile dysfunction
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4[1]. Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels[2]. Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
PRICE
29
DESCRIPTION
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4[1]. Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels[2]. Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
PRICE
70
DESCRIPTION
Vardenafil is a phosphodiesterase type 5 (PDE5A) inhibitor. Marketed formulations may contain vardenafil hydrochloride (PubChem CID 10142962).
(GtoPdb)
DESCRIPTION
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4[1]. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels[2]. Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
PRICE
29
DESCRIPTION
Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes
(TargetMol Bioactive Compound Library)
DESCRIPTION
Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Vardenafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction.
(Enamine Bioactive Compounds)
DESCRIPTION
Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
33
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
138
Molecular Weight
488.22
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
3
cLogP
2.07
TPSA
112.9
Fraction CSP3
0.52
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PDE1
PED5
phosphodiesterase
PDE5
PDE5A, PDE6G, PDE6H
PDE5 inhibitor
Endogenous Metabolite
Phosphodiesterase (PDE)
PDE
Indication
erectile dysfunction
MOA
phosphodiesterase inhibitor
Pathway
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Antiimpotence Agents
Recommended Cell Concentration
1 uM
Source data
